Inovio Pharmaceuticals Inc.

Inovio Pharmaceuticals Inc. is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon vaccines, delivered using the company's proprietary electroporation technology, are generating best-in-class immune responses, with therapeutic T cells exceeding other technologies. Inovio's lead vaccine, a therapeutic against HPV-caused precancers and cancers, is in phase 2. Other phase 1 and preclinical programs target prostate, breast and lung cancers as well as HIV, influenza, malaria and hepatitis. Roche and Inovio have an exclusive worldwide partnership to develop and commercialize Inovio's DNA immunotherapies for prostate cancer and hepatitis B.

Expert Comments:

Jason McCarthy, Maxim Group (1/28/16)
"Inovio Pharmaceuticals Inc. and partner GeneOne Life Science announced that the Phase I study of GLS-5300 (vaccine targeting Middle East Respiratory Syndrome) has initiated patient recruitment. . .the company, with GeneOne, is also rapidly moving a vaccine targeting Zika virus toward the clinic using the same pathway. . .the infectious diseases pipeline continues to move forward and generate news flow for Inovio."

Charles Duncan, Piper Jaffray & Co. (1/27/16)
"Inovio Pharmaceuticals Inc. shares are up today with reports of the first Zika virus case within U.S. borders, as earlier this week GeneOne Life Science Inc. announced expansion of its current collaboration with Inovio to develop a DNA-based Zika vaccine. The vaccine is currently preclinical, however we believe Inovio's SynCon technology is well-suited to develop Zika, and other antiviral protection via antiviral T-cells. We view the quick start of this collaboration as external validation on SynCon's flexibility and broad potential in infectious disease."

Jason Kolbert, Maxim Group (1/19/16)
"Inovio Pharmaceuticals Inc. has multiple incremental catalysts in 2016 that should aid in getting through what we see as a potential data trough (VGX-3100 pivotal study, INO-3112, Phase 2). The company has $170M in cash, which is sufficient to fund pipeline programs as well as the pivotal program for VGX-3100, in our view."

"Inovio Pharmaceuticals Inc. [has] a very interesting technology. . .I like the fact that it's not only immune therapy but also a vaccine. The therapy has a two-sided aspect to it." read more >

"Inovio Pharmaceuticals Inc. [is developing] a suite of DNA vaccines [that] effectively induce immune cell activation by getting tumor cell antigens to be expressed at higher levels, effectively creating an endogenous immune response within the patient. . .the company [generated] very positive and encouraging clinical data from a Phase 2b trial of VGX-3100, which is its lead drug candidate for the treatment of cervical cancer. . .Inovio [plans to move] into the domain of what it calls DNA monoclonal antibodies. Essentially, it plans to introduce the DNA and coding of a monoclonal antibody into the patient, and trigger the body of the patient to make the antibody. In effect, the technology primes the patient into his/her own bioreactor." read more >

Jason McCarthy, Maxim Group (1/5/16)
"Our Buy rating and long-term positive outlook on Inovio Pharmaceuticals Inc. remain unchanged. . .while multiple early stage trials are underway and/or initiating, the focus going into 2016 is the initiation of the pivotal Phase 3 study for VGX-3100, initiation of Phase 2 studies of INO-3112 with Medimmune and progress in Ebola."

More Expert Comments

Experts Following This Company

Yi Chen, Managing Director of Equity Research – Rodman & Renshaw
Charles Duncan, Managing Director, Senior Biotechnology Analyst – Piper Jaffray & Co.
Dorman Followwill, Partner and Director EIA – Frost & Sullivan Inc
Jason Kolbert, Senior Analyst – Maxim Group
Chen Lin What Is Chen Buying? What Is Chen Selling?
Jason McCarthy, Analyst – Maxim Group
Kevin McCarthy, Co-Managing Partner – Kayne Anderson MLP Investment Co.
Ram Selvaraju, Managing Director; Head of Healthcare Equity Research – Rodman & Renshaw
Ross Silver, Co-Founder and Principal Analyst – Vista Partners
Jill Wahleithner, Fund Manager – Wasatch Funds
George Zavoico, Senior Equity Analyst – JonesTrading

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.